Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
GSK pays $110M upfront for solid tumour drug rights. GSK's subsidiary has struck a licensing deal with HUTCHMED (China) for HMPL-A830, an experimental drug targeting colorectal, pancreatic, and lung cancers. The deal could be worth up to $1.3 billion in total, with a Phase I trial expected to kick off in the second half of 2026.
GSK is making a significant bet on a Chinese-developed cancer drug. The pharma giant's subsidiary, GlaxoSmithKline Intellectual Property (No. 4) Ltd, has agreed to pay $110 million upfront to HUTCHMED (China) for global rights — outside Mainland China, Hong Kong, Macau, and Taiwan — to develop and commercialize HMPL-A830, an experimental therapy targeting solid tumours.
The drug's initial clinical focus will be on colorectal, pancreatic, and lung cancers — three of the most challenging and deadly cancer types. A Phase I development programme is expected to launch in the second half of 2026, with a two-part clinical trial already registered on ClinicalTrials.gov.
By the Numbers:
Why it matters: This deal signals growing global interest in Chinese biotech innovation and reflects the continued push to develop new therapies for hard-to-treat solid tumours. For patients with colorectal, pancreatic, or lung cancer — cancers with notoriously poor prognoses — new treatment options can't come soon enough.
